Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A cycle equals 21 days and therapy will continue until radiographic progression, intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and lenvatinib are administered, patients should take the lenvatinib per their normal routine.

NCT Number	NCT04848337
Lead Sponsor	University of Michigan Rogel Cancer Center Collaborators: Merck Sharp & Dohme LLC, Hoosier Cancer Research Network
Conditions	Prostate Cancer Metastatic, Neuroendocrine Tumors
Enrollment	45 participants
Start Date	2021-05-25
Primary Completion	2025-01-08 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-05-11